Drug intelligence / Profile preview

Draxaban

Development stage: Phase 4
Lead developer: TQ Pharma
Modality: Small Molecules
Administration: Oral

Overview

Draxaban is an oral anticoagulant containing the active ingredient rivaroxaban, developed and manufactured by TQ Pharma (Al-Taqaddom Pharmaceutical Industries). It is a small molecule that acts as a direct Factor Xa inhibitor. By selectively and reversibly blocking the active site of Factor Xa, Draxaban inhibits the conversion of prothrombin to thrombin, which in turn prevents the formation of fibrin and blood clots. It is indicated for the prevention and treatment of various thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Brand names: Draxaban
Other names: rivaroxaban

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on Draxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Draxaban.

Explore the full profile